La Junta Dialysis (FMC) is a medicare approved dialysis facility center in La Junta, Colorado and it has 8 dialysis stations. It is located in Otero county at 1116 Carson Ave, La Junta, CO, 81050. You can reach out to the office of La Junta Dialysis (FMC) at (719) 383-2300. This dialysis clinic is managed and/or owned by Fresenius Medical Care. La Junta Dialysis (FMC) has the following ownership type - Profit. It was first certified by medicare in September, 1997. The medicare id for this facility is 062525 and it accepts patients under medicare ESRD program.
Name | La Junta Dialysis (FMC) |
---|---|
Location | 1116 Carson Ave, La Junta, Colorado |
No. of Dialysis Stations | 8 |
Medicare ID | 062525 |
Managed By | Fresenius Medical Care |
Ownership Type | Profit |
Late Shifts | No |
1116 Carson Ave, La Junta, Colorado, 81050 | |
(719) 383-2300 | |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
NPI Number | 1639281439 |
Organization Name | Fresenius Medical Care La Junta Dialysis |
Doing Business As | Qualicenters Pueblo, Llc |
Address | 1012 Hayes Street La Junta, Colorado, 81050 |
Phone Number | (719) 383-2300 |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
Dialysis patients with Hemoglobin data | 29 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 7 |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 41 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 408 |
Percentage of adult patients getting regular hemodialysis at the center | 98 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at La Junta Dialysis (FMC) with elevated calcium levels.
Patients with hypercalcemia | 45 |
Hypercalcemia patient months | 447 |
Patients with Serumphosphor | 46 |
Patients with Serumphosphor less than 3.5 mg/dL | 6 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 33 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
Patients with Serumphosphor greater than 7 mg/dL | 12 |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 41 |
Patient months included in arterial venous fistula and catheter summaries | 407 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 73 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 12 |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 38 |
Hospitalization Rate in facility | 70 (Better than Expected) |
Hospitalization Rate: Upper Confidence Limit | 182.7 |
Hospitalization Rate: Lower Confidence Limit | 28.6 |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at La Junta Dialysis (FMC) were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 13.6 (As Expected) |
Readmission Rate: Upper Confidence Limit | 40.5 |
Readmission Rate: Lower Confidence Limit | 2 |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at La Junta Dialysis (FMC) get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .66 (As Expected) |
SIR: Upper Confidence Limit | 2.19 |
SIR: Lower Confidence Limit | .11 |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether La Junta Dialysis (FMC)'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 35 |
Transfusion Rate in facility | 8 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 97.2 |
Transfusion Rate: Lower Confidence Limit | .9 |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at La Junta Dialysis (FMC) lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 163 |
Mortality Rate in facility | 15.5 (As Expected) |
Mortality Rate: Upper Confidence Limit | 24.4 |
Mortality Rate: Lower Confidence Limit | 9.2 |
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago
News Archive
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.
Democrats are planning to push the point this week that health care reform, with a price tag of up to $1.6 trillion, has benefits and cost savings that aren't scored by the Congressional Budget Office, The Hill reports.
In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."
BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
› Verified 9 days ago